These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effects of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nornyl)adenine on plasma levels and urinary excretion of 9-beta-D-arabinofuranosyladenine in the mouse 1,2,3. Suling WJ; Rice LS; Shannon WM Cancer Treat Rep; 1978 Mar; 62(3):369-73. PubMed ID: 647695 [No Abstract] [Full Text] [Related]
3. Toxicities of adenosine and 2'-deoxyadrenosine in L cells treated with inhibitors of adenosine deaminase. Lapi L; Cohen SS Biochem Pharmacol; 1977 Jan; 26(1):71-6. PubMed ID: 299815 [No Abstract] [Full Text] [Related]
4. Inhibition of PHA and NaI04 mitogenesis by the adenosine deaminase inhibitors erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) and 2-deoxycoformycin (2-dCF). Lum CT; Sutherland DE; Najarian JS Clin Immunol Immunopathol; 1979 Apr; 12(4):453-9. PubMed ID: 222523 [No Abstract] [Full Text] [Related]
5. Effect of chirality in erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) on adenosine deaminase inhibition. Bessodes M; Bastian G; Abushanab E; Panzica RP; Berman SF; Marcaccio EJ; Chen SF; Stoeckler JD; Parks RE Biochem Pharmacol; 1982 Mar; 31(5):879-82. PubMed ID: 7082355 [No Abstract] [Full Text] [Related]
6. Enhancement of the biological activity of adenosine analogs by the adenosine deaminase inhibitor 2'-deoxycoformycin. Adamson RH; Zaharevitz DW; Johns DG Pharmacology; 1977; 15(1):84-9. PubMed ID: 840892 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the activity of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine in vivo. Plunkett W; Alexander L; Chubb S; Loo TL Biochem Pharmacol; 1979; 28(2):201-6. PubMed ID: 426835 [No Abstract] [Full Text] [Related]
8. Inhibition of human T-cell rosette formation by the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA). Lum CT; Schmidtke JR; Sutherland DE; Najarian JS Clin Immunol Immunopathol; 1978 Jul; 10(3):258-61. PubMed ID: 307473 [No Abstract] [Full Text] [Related]
9. Adenosine deaminase inhibitors. Conversion of a single chiral synthon into erythro- and threo-9-(2-hydroxy-3-nonyl)adenines. Bastian G; Bessodes M; Panzica RP; Abushanab E; Chen SF; Stoeckler JD; Parks RE J Med Chem; 1981 Dec; 24(12):1383-5. PubMed ID: 7310814 [No Abstract] [Full Text] [Related]
10. Sedative and electroencephalographic actions of erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA): relationship to inhibition of brain adenosine deaminase. Mendelson WB; Kuruvilla A; Watlington T; Goehl K; Paul SM; Skolnick P Psychopharmacology (Berl); 1983; 79(2-3):126-9. PubMed ID: 6405420 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl)adenine in CBA mice. Lambe CU; Nelson DJ Biochem Pharmacol; 1982 Feb; 31(4):535-9. PubMed ID: 7066021 [TBL] [Abstract][Full Text] [Related]
12. Adenosine deaminase inhibitors. Synthesis of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine. Antonini I; Cristalli G; Franchetti P; Grifantini M; Martelli S; Lupidi G; Riva F J Med Chem; 1984 Mar; 27(3):274-8. PubMed ID: 6699873 [TBL] [Abstract][Full Text] [Related]
13. Niacin prevents DNA strand breakage by adenosine deaminase inhibitors. Weitberg AB; Corvese D Biochem Biophys Res Commun; 1990 Mar; 167(2):514-9. PubMed ID: 2322239 [TBL] [Abstract][Full Text] [Related]
14. Effect of erythro-9-(2-hydroxy-3-nonyl) adenine on purine and pyrimidine metabolism in the human peripheral lymphocyte during the early phases of phytohemagglutinin-mediated blastogenesis. Skupp S; Vugrek G; Ayvazian JH Biochem Pharmacol; 1979 Nov; 28(22):3323-31. PubMed ID: 526339 [No Abstract] [Full Text] [Related]
16. Erythro-9-(2-hydroxy-3-nonyl)adenine as a specific inhibitor of herpes simplex virus replication in the presence and absence of adenosine analogues. North TW; Cohen SS Proc Natl Acad Sci U S A; 1978 Oct; 75(10):4684-8. PubMed ID: 216993 [TBL] [Abstract][Full Text] [Related]
17. Inhibitors of adenosine deaminase. Studies in combining high-affinity enzyme-binding structural units. erythro-1,6-Dihydro-6-(hydroxymethyl)-9-(2-hydroxy-3-nonyl)purine and erythro-9-(2-hydroxy-3-nonyl)purine. Woo PW; Baker DC J Med Chem; 1982 May; 25(5):603-5. PubMed ID: 7086847 [TBL] [Abstract][Full Text] [Related]
18. Identification of the bioactive enantiomer of erythro-3-(adenin-9-yl)-2-nonanol (EHNA), a semi-tight binding inhibitor of adenosine deaminase. Baker DC; Hanvey JC; Hawkins LD; Murphy J Biochem Pharmacol; 1981 May; 30(10):1159-61. PubMed ID: 7259798 [No Abstract] [Full Text] [Related]
19. Effects of adenosine deaminase inhibitors on lymphocyte-mediated cytolysis. Wolberg G; Zimmerman TP Ann N Y Acad Sci; 1985; 451():215-26. PubMed ID: 3878118 [TBL] [Abstract][Full Text] [Related]
20. Erythro-9-(2-hydroxy-3-nonyl) Adenine alone and in combination with 9-beta-D-arabinofuranosyladenine in treatment of systemic herpesvirus infections in mice. Shannon WM; Arnett G; Schabel FM; North TW; Cohen SS Antimicrob Agents Chemother; 1980 Oct; 18(4):598-603. PubMed ID: 6255863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]